3 active not recruiting, 3 unknown, 1 not yet recruiting. 7 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Active not recruiting 3, Unknown 3, Not yet recruiting 1 |
| Phase 2 | 6 | Active not recruiting 3, Unknown 2, Not yet recruiting 1 |
Follow R-CHOP protocol: new trials by email Literature Review of R-CHOP protocol trials Research Report on R-CHOP protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study R-CHOP, POLA-R-CHP, Lisaftoclax - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 122 | 2026-02-28 | 2026-02-10 |
| Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients Selinexor, R-CHOP Protocol - EBV-Positive Diffuse Large B-Cell Lymphoma, Nos | Phase 1 / Phase 2 | Unknown | Sun Yat-sen University | 54 | 2022-11-01 | 2023-12-14 |
| To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) tafasitamab, lenalidomide, parsaclisib - Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Incyte Biosciences Japan GK | 72 | 2020-12-15 | 2026-10-21 |
| Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab and lenalidomide, rituximab and bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Genmab | 543 | 2020-11-03 | 2026-11-03 |
| Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) Epcoritamab (monotherapy), Epcoritamab, Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Genmab | 78 | 2020-08-20 | 2026-11-04 |
| PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients Vincristine Sulfate Liposome, CHOP, R-CHOP - Hematologic Diseases | Phase 1 | Unknown | Acrotech Biopharma Inc. | 56 | 2020-08-15 | 2020-04-16 |
| Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 140 | 2020-04-24 | 2022-04-14 |
Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Follicular (2) · Pyloric Stenosis, Hypertrophic (2) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Non-Hodgkin (1)
Genmab (2) · Sun Yat-sen University (2) · Acrotech Biopharma Inc. (1) · Huiqiang Huang (1) · Incyte Biosciences Japan GK (1)
China (3) · Japan (2) · Australia (1) · Belgium (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Italy (1) · Netherlands (1) · Norway (1) · Spain (1) · Sweden (1) · United Kingdom (1) · United States (1)
Wasim Khan, MD (1)
PMID 39792928, PMID 40632620, PMID 40920572, PMID 41563911, PMID 41784015, PMID 42411504, PMID 42541678, PMID 42622258, PMID 42660129
2023 (1)